On June 30, 2025, the Ordinary General Meeting of the Company approved the financial statements for the fiscal year from January 1...
On June 27, 2024, the Ordinary General Meeting of the Company approved the financial statements for the period from August 1, 2022...
On January 3, 2024, the Company’s Extraordinary Shareholders’ Meeting made changes to the Company’s Management Board. As of...
On August 4, 2023, the Extraordinary Shareholders’ Meeting of the Company issued 1 to 2,592,593 series D shares. The final numbe...
The Company’s Annual Shareholders’ Meeting was held on January 31, 2023, which approved the Company’s financial statements f...
On 8th September 2021, the registry court registered a change of the Article 38 of the Company’s charter and adoption of the con...
On 18th August 2021, the Extraordinary General Meeting of shareholders of the Company adopted resolutions concerning modification...
On 7th June 2021, the registry court registered a change of the Company’s name from HELIX IMMUNO-ONCOLOGY S.A. to a new one, nam...
On 24th March 2021, the Extraordinary General Meeting of shareholders of the Company adopted resolutions concerning modification o...
On February 2, 2021, HELIX IMMUNO-ONCOLOGY S.A. submitted the following documents to the Financial Document Repository for the fis...